Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

NCT00737243 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

289

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Bevacizumab
DRUG: Erlotinib
OTHER: Treatment determined by physician

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]